PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bioinorgchemapplJournal's HomeManuscript SubmissionAims and ScopeAuthor GuidelinesEditorial BoardHome
 
Bioinorg Chem Appl. 2010; 2010: 914580.
Published online 2010 June 23. doi:  10.1155/2010/914580
PMCID: PMC2905951

In Search for Titanocene Complexes with Improved Cytotoxic Activity: Synthesis, X-Ray Structure, and Spectroscopic Study of Bis(η5-cyclopentadienyl)difluorotitanium(IV)

Abstract

The 1 : 2 reaction of [Ti(η5-C5H5)2Cl2] and AgF in CHCl3/H2O yielded the fluoro analog [Ti(η5-C5H5)2F2] (1) in almost quantitative yield (C5H5 is the cyclopentadienyl group). The coordination about the TiIV atom formed by two fluoro ligands and the centroids of the cyclopentadienyl rings is distorted tetrahedral. The compound crystallizes in the orthorhombic space group C2cm. The lattice constants are a = 5.9055(4), b = 10.3021(5), c = 14.2619(9) Å, and α = β = γ = 90°. The complex has been characterized by elemental analyses and spectroscopic (IR, 1H NMR) data. A structural comparison of the four members of the [Ti(η5-C5H5)2X2] family of complexes (X = F, Cl, Br, I) is attempted.

1. Introduction

One of the first metal complexes discovered to exhibit biological activity has been cisplatin, [Pt(NH3)2Cl2] [1]. It is considered as one of the most efficient drugs for the treatment of certain types of cancer; however, drug toxicity and resistance limit its utilization for a broader range of diseases. In recent years, there has been a growing interest in the development of nonplatinum-based anticancer therapeutics. The main goal is to increase the variety of potential drugs, which may lead to higher activities enabling the administration of lower doses, attack of different types of tumour cells, solution of drug resistance problems, better selectivity and to lower toxicity. Non-platinum complexes may introduce numerous options for coordination numbers and geometries, oxidation states, affinity for certain types of biological ligands, and so forth, and may thus operate by different mechanisms. One class of such complexes are metallocene dihalides.

Metallocene dihalides, [M(η5-C5H5)2X2] (M = Ti, V, Nb, Mo, Re; X = halide ligand; C5H5 = Cp, the cyclopentadienyl group), are a relatively new class of small hydrophobic organometallic anticancer agents that exhibit antitumour activities against cancer cell lines, such as leukaemias P388 and L1210, colon 38 and Lewis lung carcinomas, B16 melanoma, solid and fluid Ehrlich ascites tumours and also against human colon, renal and lung carcinomas transplanted into athymic mice [25]. Titanocene dichloride, [Ti(η5-C5H5)2Cl2], is the most widely studied metallocene compound as a cytotoxic anticancer agent, which means that it can selectively kill cancer cells, and was used in phase I and II clinical trials [613]. However, the efficacy of [Ti(η5-C5H5)2Cl2] in phase II clinical trials in patients with metastatic renal cell carcinoma [12] or metastatic breast cancer [13] was too low to be pursued. As titanium is present in many biomaterials, such as in food in the form of a whitening pigment, it is not unreasonable to conceive that it may be incorporated into drugs and into living systems, with particularly low toxicity [14].

In 2008, a novel class of substituted titanocene dichlorides, the so-called “benzyl-substituted titanocenes”, with improved cytotoxic activity were developed and tested for their potential application as anticancer drugs [15]. The cytotoxic activity can also be influenced by substitution of the two chloride ligands. More recently, Huhn and co-workers reported the synthesis and cytotoxicity of selected benzyl-substituted fluorotitanocene derivatives that showed a cytotoxic activity 3–5 fold higher than that of the respective dichlorides [16]. In the same paper, the X-ray structure analysis of two of the titanocene difluoride derivatives was also described. The prototype of the latter compounds is titanocene difluoride, [Ti(η5-C5H5)2F2], which itself (i) exhibits strong antitumor, anti-inflammatory and anti-arthritic activity as well as immunosuppressant effects [17, 18], (ii) reduces significantly the rates of crystal growth of hydroxyapatite (the model compound for the inorganic component of bones and teeth, observed in pathological calcifications of the articular cartilage) [19], and (iii) is an effective catalyst for the reduction of lactones and imines, reductive-deoxygenative coupling of amides, hydrogenation of olefins, and defluorination of saturated perfluorocarbons [20].

Surprisingly, the crystal structure of bis(η5-cyclopentadienyl)difluorotitanium(IV) is not known. In the present work, we describe the first X-ray diffraction study of [Ti(η5-C5H5)2F2], providing structural data which will probably be important in structure-activity investigations of new titanocene difluorides, a promising class in terms of medical applications.

2. Experiments

Reagents and solvents were purchased from commercial sources, and were purified (where necessary) and dried before use by standard procedures. The starting titanocene dichloride, [Ti(η5-C5H5)2Cl2], was synthesized under an argon atmosphere using dried THF by the method of Wilkinson and Birmingham [21] and recrystallized from boiling toluene. All manipulations were performed under aerobic conditions. Microanalyses (C, H) were performed by the University of Patras (Greece) Microanalytical Laboratory using an EA 1108 Carlo Erba analyzer. IR spectra (4000–450 cm−1) were recorded on a Perkin-Elmer 16 PC FT-spectrometer with samples prepared as KBr pellets. The 1H NMR spectrum of the complex in CDCl3 was recorded with a Bruker Avance 400 MHz spectrometer; chemical shifts are reported relative to tetramethylsilane. Conductivity measurements were carried out at 25°C using an Ehrhardt-Metzger, type L21, conductivity bridge.

[Ti(η5-C5H5)2F2] (1) was synthesized in a plastic bottle from a solution of the dichloride, [Ti(η5-C5H5)2Cl2] (5 mmol), in CHCl3 by adding a freshly prepared aqueous solution of AgF (10 mmol) according to the procedure described in [22]. The reaction mixture was shaken vigorously for 20 minutes at room temperature. During this time, the colour of the organic phase changed from red to orange and finally to yellow. The yellow CHCl3 phase was separated from the aqueous phase, containing the white precipitate of AgCl, through a separatory funnel and filtered. Condensation of the yellow filtrate under reduced pressure gave a fluffy lemon-yellow solid that was dried in vacuo over silica gel and recrystallized from toluene. Yield 90% and m.p. 235°C (dec.) Lemon-yellow, needle-like crystals of 1 suitable for X-ray analysis were obtained by vapour diffusion of petroleum ether into a CHCl3 solution of the product placed in an H-shaped tube. Anal. Calc. for C10H10F2Ti (216.08): C, 55.59; H, 4.66. Found: C, 55.28; H, 4.62. Selected IR data (KBr, cm−1): 3108 (s), 1442 (s), 1362 (w), 1016 (s), 874 (m), 822 (vs), 610 (w), 564 (s), 539 (m). 1H NMR (400 MHz, CDCl3): δ 6.53 (t).

2.1. X-Ray Crystallographic Studies

A yellow prismatic crystal of 1 was taken directly from the mother liquid and immediately cooled to −113°C. Diffraction measurements were made on a Rigaku R-AXIS SPIDER Image Plate diffractometer using graphite monochromated Cu Kα radiation. Data collection (ω-scans) and processing (cell refinement, data reduction and empirical absorption correction) were performed using the CRYSTALCLEAR program package [23]. Important crystal data and parameters for data collection and refinement are listed in Table 1. The structure was solved by direct methods using SHELXS-97 [24] and refined by full-matrix least-squares techniques on F2 with SHELXL-97 [25]. Hydrogen atoms of the cyclopentadienyl (Cp) group were introduced at calculated positions as riding on bonded atoms. All non-H atoms were refined anisotropically. In the structure of 1, the carbon atoms of one of the two Cp rings are disordered over symmetry-related positions. CCDC 771089 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge at http://www.ccdc.cam.ac.uk/conts/retrieving.hmtl (or from the Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; Fax: (internat.) ++ 44-1223/336-033; E-mail: deposit/at/ccdc.cam.ac.uk).

Table 1
Crystallographic data and structure refinement for complex 1.

3. Results and Discussion

3.1. Synthetic Comments

The title compound was first prepared by Wilkinson and Birmingham in 1954 by dissolving the bromo analog, [Ti(η5-C5H5)2Br2], in hot 12 N hydrofluoric acid and heating on a steam-bath until the solution was pale yellow in colour. On cooling, yellow crystals were received which were recrystallized from 3 N hydrofluoric acid solution [21]. Among the other published in the literature methods, we selected that described by Pink in his Thesis. The method uses AgF prepared in situ, which gives the best yields in the shortest time [29]. The preparation of 1 involves the reactions represented by the stoichiometric equations (1)–(3):

equation M1
(1)

equation M2
(2)

equation M3
(3)

The two first steps ((1) and (2)) are necessary because AgF decomposes upon staying. Experiments with commercial AgF always lead to poor yields. Another method for a high-yield synthesis of 1 was developed by Ruzicka and coworkers [30] and involves the 1  :  2 reaction of [Ti(η5-C5H5)2Cl2] and the good fluorinating agent {2-[(CH3)2NCH2]C6H4}(n-Bu)2SnF in CH2Cl2.

Complex 1 is, like [Ti(η5-C5H5)2Cl2], a very stable compound. It dissolves easily in common organic solvents such as chloroform, methanol, benzene, toluene and is much more soluble in water than are the other congener halides, even at room temperature, without decomposition. A decent water solubility is essential for a satisfactory cytotoxic activity of titanium(IV) complexes. Its molar conductivity (H2O, 10−3 M, 25°C) is less than 5 S cm2 mol−1. This means that, in contrast to the other corresponding titanocene dihalides, the fluoride ligands in 1 are hydrolytically stable. In this case, the water solubility and negligible molar conductivity could be attributed to the formation of hydrogen bonds between the electronegative F ligands of 1 and the H2O molecules rather than to a dissociation of the complex to species like [Ti(η5-C5H5)2(H2O)2]2+ and F. The oxophilicity of TiIV makes complexes of this metal ion with organic and inorganic ligands highly susceptible to hydrolysis. Complexes of hydrolytic instability are not biologically active, probably due to rapid formation of inactive aggregates [14].

3.2. Spectroscopic Characterization

The IR spectra of π-bonded cyclopentadienyl metal complexes have been studied [3133]. In the IR spectrum of 1 the bands at 3108, 1442, 1016, 874/822 and 610 cm−1 can be assigned [3133] to the ν(CH), ν(CC), δ(CH), π(CH) and δ(CCC) vibrational modes, respectively. The bands at 564 and 539 cm−1 are assigned [32] to the ν1(A1) and ν6(B1) (under C2V point group symmetry) stretching modes of the terminal TiIV-F bonds.

The 1H NMR spectrum (CDCl3) of 1 shows a triplet peak at δ = 6.53 ppm corresponding to the equivalent protons of the η5-C5H5 protons [31, 34]. The triplet character of the signal is due to the small 3J coupling (1.7 Hz) between the cyclopentadienyl protons and the fluoro nuclei in the molecule [34].

3.3. Description of Structure

The molecular structure and a crystal packing diagram of 1 are shown in Figures Figures1 and1 and and2,2, respectively. Bond lengths and angles are listed in Table 2.

Figure 1
Labeled PovRay representation of complex 1 with the atom numbering scheme. Primes are used for symmetry-related atoms. Colour scheme: TiIV, yellow; F, blue; C, gray; H, purple.
Figure 2
Drawing of the crystalline packing of complex 1.
Table 2
Selected bond lengths (Å) and angles (°) for complex 1.a

The structure of 1 consists of isolated [TiIV(η5-C5H5)2F2] molecules. The molecule has the familiar, distorted tetrahedral shape found in the chloro [26], bromo [27] and iodo [28] members of the [TiIV(η5-C5H5)2X2] family of complexes. The distorted tetrahedral structure arises if we consider the Cp ring centroids as each occupying one coordination site around the metal ion. The cyclopentadienyl centroid-titanium-cyclopentadienyl centroid angle is 128.53°, and the fluorine-titanium-fluorine angle is 96.0°. The TiF2 group defines a symmetry plane and there is thus one crystallographically independent Cp ligand. The plane defined by the TiIV atom and the centroids of the Cp rings bisects the F-Ti-F bond angle. Thus, the molecule has a 2-fold symmetry about the line of intersection of this plane and the plane of the F-Ti-F bond angle; its point group symmetry is C2v. The Cp ring is planar to ±0.019 Å. The least-squares planes of the two symmetry related Cp rings in the bent (Cp)2Ti fragment of 1 form a dihedral angle of 53.49°. The two Cp rings exhibit a staggered conformation. The angle between the normals to ring planes is 53.83°.

The five Ti-C bond lengths range from 2.363(9) to 2.400(11) Å. This narrow range establishes a distinct pentahapto coordination mode for each Cp ligand in 1. The mean Ti-C bond distance (2.380 Å) is in agreement with the corresponding values of other bis(cyclopentadienyl)titanium(IV) complexes, for example, the value of 2.370 Å in [Ti(η5-C5H5)2Cl2] [26]. The TiIV-F bond distances [1.853(4), 1.859(4) Å] are similar to those found in other 4-coordinate titanium(IV) complexes containing terminal Ti-F bonds [16, 35, 36]. The C-C bond lengths in the Cp ring of 1 with an average value of 1.388 Å are within the usual range reported for organometallic complexes containing Cp rings [27].

Since the single-crystal, X-ray structures of all the four members of the [Ti(η5-C5H5)2X2] (X = F, Cl, Br, I) family are now known, we feel it is interesting to compare some of their important structural and crystallographic parameters. The comparisons are presented in Tables Tables3 and3 and and4,4, respectively. The average distance from the TiIV atom to the ring centroid and the angle between the vectors from the metal center to each of the ring centroids vary by less than 0.025 Å and 4°, respectively, across the four complexes. The F-Ti-F angle (96.0°) is slightly wider than the corresponding X-Ti-X (X = Cl, Br, I) angles (92.8–94.5°) suggesting that electronic, rather than steric, effects influence this angle. The fluoro complex 1 has the largest X-Ti-X and the smallest Cp-Ti-Cp angle. As expected, the average titanium-halogen distances follow the sequence Ti-F < Ti-Cl < Ti-Br < Ti-I.

Table 3
Comparison of some important molecular parameters (average values) for the four prototype titanocene dihalogenides, [Ti(η5-C5H5)2X2].
Table 4
Comparison of unit cell parameters for the four prototype titanocene dihalogenides, [Ti(η5-C5H5)2X2].

4. Conclusions

The important message of this work is that we have structurally characterized the last member, namely the fluoro complex, of the [Ti(η5-C5H5)2X2] (X = halogenide) family of complexes. Although the preparation of 1 was reported ~55 years ago, its exact molecular and crystal structure remained unknown until our report in this work. Studies are now underway in our laboratories to investigate the reactivity pattern of 1 with bidentate and tridentate N- or/and O-based ligands, and to study the hydrolytic behavior and cytotoxic activities of the resulting products. It should be mentioned that the fluoride ions themselves, if present in the products, are not cytotoxic at concentrations below 10−3 M [16].

Acknowledgment

This paper is dedicated to Professor Dr. Nick Hadjiliadis for his contribution to the advancement of Bioinorganic Chemistry.

References

1. Lippard SJ, Berg JM. Principles of Bioinorganic Chemistry. Mill Valley, Calif, USA: University Science Books; 1994.
2. Köpf-Maier P. Tumor inhibition by metallocenes: ultrastructural localization of titanium and vanadium in treated tumor cells by electron energy loss spectroscopy. Naturwissenschaften. 1980;67:415–426. [PubMed]
3. Köpf-Maier P. Antitumor activity of titanocene dichloride in xenografted human renal-cell carcinoma. Anticancer Research. 1999;19(1 A):493–504. [PubMed]
4. Harding MM, Modski G. Antitumor metallocenes: structure-activity studies and interactions with biomolecules. Current Medical Chemistry. 2000;7:1289–1303. [PubMed]
5. Mokdsi G, Harding MM. Inhibition of human topoisomerase II by the antitumor metallocenes. Journal of Inorganic Biochemistry. 2001;83(2-3):205–209. [PubMed]
6. Christodoulou CV, Ferry DR, Fyfe DW, et al. Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer. Journal of Clinical Oncology. 1998;16(8):2761–2769. [PubMed]
7. Mross K, Robben-Bathe P, Edler L, et al. Phase I clinical trial of a day-1, -3, -5 every 3 weeks schedule with titanocene dichloride (MKT 5) in patients with advanced cancer: a study of the phase I study group of the association for medical oncology (AIO) of the German Cancer Society. Onkologie. 2000;23(6):576–579. [PubMed]
8. Korfel A, Scheulen ME, Schmoll H-J, et al. Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors. Clinical Cancer Research. 1998;4(11):2701–2708. [PubMed]
9. Desoize B. Metals and metal compounds in cancer treatment. Anticancer Research. 2004;24(3 A):1529–1544. [PubMed]
10. Caruso F, Rossi M. Antitumor titanium compounds. Mini-Reviews in Medicinal Chemistry. 2004;4(1):49–60. [PubMed]
11. Meléndez E. Titanium complexes in cancer treatment. Critical Reviews in Oncology/Hematology. 2002;42(3):309–315. [PubMed]
12. Lümmen G, Sperling H, Luboldt H, Otto T, Rübben H. Phase II trial of titanocene dichloride in advanced renal-cell carcinoma. Cancer Chemotherapy and Pharmacology. 1998;42(5):415–417. [PubMed]
13. Kröger N, Kleeberg UR, Mross K, Edler L, Saß G, Hossfeld DK. Phase II clinical trial of titanocene dichloride in patients with metastatic breast cancer. Onkologie. 2000;23(1):60–62.
14. Tshuva EY, Peri D. Modern cytotoxic titanium(IV) complexes; insights on the enigmatic involvement of hydrolysis. Coordination Chemistry Reviews. 2009;253(15-16):2098–2115.
15. Strohfeldt K, Tacke M. Bioorganometallic fulvene-derived titanocene anti-cancer drugs. Chemical Society Reviews. 2008;37(6):1174–1187. [PubMed]
16. Eger S, Immel TA, Claffey J, et al. Titanocene difluorides with improved cytotoxic activity. Inorganic Chemistry. 2010;49(4):1292–1294. [PubMed]
17. Köpf-Maier P, Hesse B, Voigtlaender R, Köpf H. Tumor inhibition by metallocenes: antitumor activity of titanocene dihalides (C5H5)2TiX2(X = F, Cl, Br, I, NCS) and their application in buffered solutions as a method for suppressing drug-induced side effects. Journal of Cancer Research and Clinical Oncology. 1980;97(1):31–39. [PubMed]
18. Fairlie DP, Whitehouse MW, Broomhead JA. Irritancy and anti-inflammatory activity of bis(η5-cyclopentadienyl)titanium(IV) complexes in rats. Chemico-Biological Interactions. 1987;61(3):277–291. [PubMed]
19. Dalas E, Klouras N, Maniatis C. Inhibition of hydroxyapatite formation by titanocenes. Langmuir. 1992;8(3):1003–1006.
20. Carson MW, Lilly E. Encyclopedia of Reagents for Organic Synthesis. John Wiley & Sons; 2003. Difluorobis(cyclopentadienyl)titanium.
21. Wilkinson G, Birmingham JM. Bis-cyclopentadienyl compounds of Ti, Zr, V, Nb and Ta. Journal of the American Chemical Society. 1954;76(17):4281–4284.
22. Brauer G. Handbuch der Präparativen Anorganischen Chemie. 6th edition. Vol. 1. Stuttgart, Germany: F. Enke; 1962.
23. Rigaku/MSC. Crystal Clear. The Woodlands, Tex, USA: Rigaku/MSC; 2005.
24. Sheldrick GM. SHELXS-97: Structure Solving Program. Göttingen, Germany: University of Göttingen; 1997.
25. Sheldrick GM. SHELXL-97: Crystal Structure Refinement Program. Göttingen, Germany: University of Göttingen; 1997.
26. Clearfield A, Warner DK, Saltarriaga-Molina CH, Ropal R, Bernal I. Structural studies of (π-C5H5)2MX2 complexes and their derivatives. The structure of bis(π-cyclopentadienyl)titanium dichloride. Canadian Journal of Chemistry. 1975;53:1622–1629.
27. Klouras N, Nastopoulos V, Demakopoulos I, Leban I. Molecular and crystal structure of bis(cyclopentadienyl)titanium(IV) dibromide, Ti(η5-C5H5)2Br2. Zeitschrift für Anorganische und Allgemeine Chemie. 1993;619:1927–1930.
28. Strunkina LI, Minacheva MKh, Lyssenko KA, et al. Interaction of titanium(III) zwitterionic complex Cp[η5-C5H4B(C6F5)3]Ti with organic halides: synthesis and X-ray crystal structure determination of zwitterionic titanocene monohalides. Journal of Organometallic Chemistry. 2006;691(4):557–565.
29. Pink H. Über reaktionen von biscyclopentadienyl-titan(IV)-verbindungen (C5H5)2TiX2 mit hydriden und doppelhydriden. München, Germany: 1959. Doctorate thesis.
30. Bareš J, Novák P, Nádvorník M, et al. Monomeric triorganotin(IV) fluorides containing a C,N-chelating ligand. Organometallics. 2004;23(12):2967–2971.
31. Druce PM, Kingston BM, Lappert MF, Spalding TR, Srivastava RC. Metallocene halides. Part I. Synthesis, spectra, and redistribution equilibria of di-π-cyclopentadienyldihalogeno-titanium(IV),-zirconium-(IV), and -hafnium(IV) Journal of the Chemical Society A. 1969:2106–2110.
32. Nakamoto K. Infrared and Raman Spectra of Inorganic and Coordination Compounds. 4th edition. New York, NY, USA: John Wiley & Sons; 1986.
33. Hartley D, Ware MJ. The vibrational spectra and assignment of bis-(π-cyclopentadienyl)- iron(II) and the bis-(π-cyclopentadienyl)cobalt(III) cation. Journal of the Chemical Society A. 1969:138–142.
34. Banger KK, Brisdon AK. The first early transition metal perfluorovinyl complexes: the synthesis of Cp2M(CF=CF2)nX2−n(Cp = η5-C5H5; M = Ti, Zr; X = Cl or F) and structures of Cp2Ti(CF=CF2)nX2−n(X = Cl, F) via Ti K-edge EXAFS studies. Journal of Organometallic Chemistry. 1999;582(2):301–309.
35. Winter CH, Zhou X-X, Heeg MJ. Approaches to hexane-soluble cationic organometallic Lewis acids. Synthesis, structure, and reactivity of titanocene derivatives containing polysilylated cyclopentadienyl ligands. Inorganic Chemistry. 1992;31(10):1808–1815.
36. Edwards AJ, Burke NJ, Dobson CM, Prout K, Heyes SJ. Solid state NMR and X-ray diffraction studies of structure and molecular motion in ansa-titanocenes. Journal of the American Chemical Society. 1995;117(16):4637–4653.

Articles from Bioinorganic Chemistry and Applications are provided here courtesy of Hindawi Publishing Corporation